Leary, A., Gorp, T. V., Marmé, F., Paoletti, X., Eberst, L., Angelergues, A., Lebreton, C., Quesada, S., Rouge, T. D. L. M., You, B., Sabatier, R., Mansi, L., Kaczmarek, E., Alexandre, J., Grellety, T., Combe, P., Hardy-Bessard, A., Gladieff, L., Frenel, J., Ray-Coquard, I. L. (2026). The neo-epitope-based vaccine OSE2101 with or without pembrolizumab versus best supportive care as maintenance in platinum-sensitive recurrent ovarian cancer patients with controlled disease after platinum-based chemotherapy: The academic randomized TEDOVA/GINECO-OV244b/ENGOT-ov58 trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.5510